CD44 and in situ carcinoma: The expression of TOB1, CD44, FOXP3, TBX21 and RORC genes were measured in CD4+ T cells from 10 healthy controls, 20 CIS patients within 3 months of initial clinical presentation and 10 relapsing remitting MS patients sampled within 2 months of relapse.